Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | APP | P05067 | 4/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8024005 | 0.89 | ATM (0.79) | ATMAPPCTSSCTSLCTSB | |
| SCHEMBL13770952 | 0.88 | ATM (0.77) | ATMAPPCTSSCTSLCTSB | |
| SCHEMBL13780925 | 0.88 | ATM (0.66) | ATMAPPCTSSCTSLCTSB | |
| SCHEMBL15159951 | 0.86 | ATM (0.73) | ATMAPPCTSSCTSLCTSB | |
| SCHEMBL13770951 | 0.85 | ATM (0.65) | ATMAPPCTSSCTSLCTSB | |
| SCHEMBL13995497 | 0.85 | ATM (0.68) | ATMAPPCTSSCTSLCTSB | |
| SCHEMBL13995499 | 0.85 | ATM (0.68) | ATMAPPCTSSCTSLCTSB | |
| SCHEMBL270485 | 0.83 | ATM (0.87) | ATMAPPCTSSCTSLCTSB | |
| SCHEMBL270486 | 0.83 | ATM (0.87) | ATMAPPCTSSCTSLCTSB | |
| SCHEMBL271598 | 0.83 | ATM (0.87) | ATMAPPCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9849107-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160361287-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9233952-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2231628-B1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-8952056-B2 | Methods for inhibiting drug degradation | SEQUOIA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8759379-B2 | Inhibitors of cytochrome P450 | GILEAD SCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759379-B2 | Inhibitors of cytochrome P450 | GILEAD SCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8673970-B2 | HIV protease inhibitor and cytochrome p450 inhibitor combinations | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140024671-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS INC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20110098237-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2010077317-A2 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2009105781-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105782-A1 | HIV PROTEASE INHIBITOR AND CYTOCHROME P450 INHIBITOR COMBINATIONS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009088719-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008022345-A2 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | ATM 3866/4885APP 1021/4885CTSS 673/4885 |
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP11B2, CYP2F1 | ATM 4182/4885APP 4191/4885CTSS 1167/4885 |
| US-20160361287-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | ATM 3866/4885APP 1021/4885CTSS 673/4885 |
| US-20140024671-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | ATM 3866/4885APP 1021/4885CTSS 673/4885 |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | CYP2E1, CYP3A43, CYP3A5 | ATM 3254/4885APP 935/4885CTSS 253/4885 |
| US-20110098237-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | CYP2E1, CYP3A43, CYP3A5 | ATM 3254/4885APP 935/4885CTSS 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.